Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 2/20 | 0.51 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.51 |
| ▸ | HDAC6 | Q9UBN7 | 5/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.43 |
| ▸ | TBXA2R | P21731 | 3/20 | 0.42 |
| ▸ | PTGDR | Q13258 | 3/20 | 0.42 |
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.42 |
| ▸ | FABP4 | P15090 | 2/20 | 0.42 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | DRD1 | P21728 | 1/20 | 0.41 |
| ▸ | CCKAR | P32238 | 1/20 | 0.41 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.40 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16750332 | 0.90 | TRPM8 (0.48) | ENPP2TRPM8HDAC6HDAC1HDAC10 | |
| SCHEMBL30426169 | 0.87 | ENPP2 (0.55) | ENPP2TRPM8HDAC6HDAC1TBXA2R | |
| SCHEMBL16742442 | 0.87 | ENPP2 (0.55) | ENPP2TRPM8HDAC6HDAC1TBXA2R | |
| SCHEMBL16742444 | 0.87 | ENPP2 (0.55) | ENPP2TRPM8HDAC6HDAC1TBXA2R | |
| Hydrochloric Acid SCHEMBL18044813 | 0.86 | ENPP2 (0.54) | ENPP2TRPM8HDAC6HDAC1TBXA2R | |
| Hydrochloric Acid SCHEMBL18044814 | 0.86 | ENPP2 (0.54) | ENPP2TRPM8HDAC6HDAC1TBXA2R | |
| SCHEMBL16750316 | 0.83 | ENPP2 (0.50) | ENPP2TRPM8HDAC6HDAC1TBXA2R | |
| SCHEMBL8381090 | 0.79 | CA1 (0.49) | ENPP2HDAC6HDAC1FABP4DRD1 | |
| SCHEMBL11017941 | 0.79 | CA1 (0.49) | ENPP2HDAC6HDAC1FABP4DRD1 | |
| SCHEMBL18044824 | 0.77 | ENPP2 (0.49) | ENPP2HDAC6HDAC1HDAC10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180162859-A1 | TETRACYCLIC AUTOTAXIN INHIBITORS | ATXCO, INC. | 2018-06-14 | — | — | US | disclosed |
| US-9926318-B2 | Tetracyclic autotaxin inhibitors | PHARMAKEA, INC. (US) | 2018-03-27 | — | — | US | disclosed |
| US-20160264575-A1 | TETRACYCLIC AUTOTAXIN INHIBITORS | DF 2024 IP ACQUISITION, LLC | 2016-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180162859-A1 | TETRACYCLIC AUTOTAXIN INHIBITORS | ENPP2, SERPINB1, UACA | ENPP2 1/4885TRPM8 2058/4885HDAC6 195/4885 |
| US-20160264575-A1 | TETRACYCLIC AUTOTAXIN INHIBITORS | ENPP2, SERPINB1, UACA | ENPP2 1/4885TRPM8 2058/4885HDAC6 195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.